USA - engelsk - NLM (National Library of Medicine)

sandoz inc - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate 3 mg - estradiol valerate and estradiol valerate/dienogest is indicated for use by women to prevent pregnancy. the efficacy of estradiol valerate and estradiol valerate/dienogest in women with a body mass index (bmi) of > 30 kg/m2 has not been evaluated. estradiol valerate and estradiol valerate/dienogest is also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception [see clinical studies (14.2)]. do not prescribe estradiol valerate and estradiol valerate/dienogest to women who are known to have the following: there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. the administration of cocs to induce w

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

viatris sante - éthinylestradiol 0; drospirénone 3 mg - comprimé - 0,02 mg - pour un comprimé > éthinylestradiol 0,02 mg > drospirénone 3 mg - pharmaco-thérapeutique (atc) progestatifs et estrogènes. associations fixes - drospirenone/ethinylestradiol viatris 3 mg/0,02 mg, comprimé pelliculé est une pilule contraceptive utilisée afin d’éviter une grossesse.chaque comprimé contient une faible quantité de deux différentes hormones féminines : la drospirénone et l'éthinylestradiol.les contraceptifs oraux qui contiennent deux hormones sont appelés contraceptifs oraux « combinés » (coc).

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

viatris sante - éthinylestradiol 0; drospirénone 3 mg - comprimé - 0,02 mg - rose (comprimé actif pour un comprimé > éthinylestradiol 0,02 mg > drospirénone 3 mg comprimé blanc (comprimé placebo > pas de substance active. - pharmaco-thérapeutique (atc) progestatifs et estrogènes. associations fixes - drospirenone/ethinylestradiol viatris continu 3 mg/0,02 mg, comprimé pelliculé est une pilule contraceptive utilisée afin d'éviter une grossesse.chacun des 21 comprimés roses contient une faible quantité de deux différentes hormones féminines : la drospirénone et l'éthinylestradiol.les 7 comprimés blancs ne contiennent pas de substances actives et sont aussi appelés des comprimés placebo.les contraceptifs oraux qui contiennent deux hormones sont appelés contraceptifs oraux « combinés » (coc).

USA - engelsk - NLM (National Library of Medicine)

heritage pharmaceuticals inc - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg - estradiol tablets, usp is indicated in the: 1.treatment of moderate to severe vasomotor symptoms associated with the menopause. 2.treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 5. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). 6. prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology, clinical studies.) the mainstays for decreasing the risk of postmeno

USA - engelsk - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg - estradiol tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies. ) - the mainstays for decreasing the risk of postmenopau

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg - estradiol tablets are indicated in the: estrogens should not be used in individuals with any of the following conditions:

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg - estradiol tablets are indicated in the: 1.    treatment of moderate to severe vasomotor symptoms associated with the menopause.  2.    treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribed solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.  3.    treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4.    treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 5.    treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). 6.    prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate (see clinical pharmacology, clinical studies .) the mainstays for decreasing the

Slovenia - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

etinilestradiol; etinilestradiol; etonogestrel - vaginalni dostavni sistem - etinilestradiol 2,7 mg / 1 sistem  etinilestradiol2,7 mg / 1 sistem  etonogestrel11,7 mg / 1 sistem; etinilestradiol 2,7 mg / 1 sistem  etonogestrel11,7 mg / 1 sistem; etonogestrel 11,7 mg / 1 sistem - vaginalni obroček s progestogenom in estrogenom

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

cristers - éthinylestradiol 15 microgrammes; gestodène 60 microgrammes - comprimé - 15 microgrammes - jaune pour un comprimé > éthinylestradiol 15 microgrammes > gestodène 60 microgrammes comprimé blanc > pas de substance active. - progestatifs et estrogenes en association fixe. - gestodene/ethinylestradiol cristers est une pilule contraceptive orale utilisée afin d'éviter une grossesse.chacun des 24 comprimés jaunes contient une faible quantité de deux hormones féminines, appelées le gestodène et l'éthinylestradiol.les 4 comprimés blancs ne contiennent pas de substance active et sont appelés comprimés placebos.les pilules contraceptives qui contiennent deux hormones sont appelées pilules contraceptives « combinées ».

USA - engelsk - NLM (National Library of Medicine)

direct rx - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets usp are indicated in the: treatment of moderate to severe vasomotor symptoms associated with the menopause. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology, clinical studies.) the mainstays for decreasing the risk of